Temporal Changes in Biomarkers, Functional Status, and Quality of Life Prior to Adverse Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction

In a large HFmrEF/HFpEF trial population, clinically meaningful changes in readily available biomarkers, functional status, and patient-reported health status were observed in the months leading up to a clinical event. Monitoring these parameters may help identify patients at high risk for near-term adverse clinical events. (Finerenone Trial to Investigate the Efficacy and Safety Superior to Placebo in Patients With Heart Failure [FINEARTS-HF]; NCT04435626).

Authors

Institutions

Publication Details

Journal
JACC Heart Failure
Published
2025-08-25
DOI
https://doi.org/10.1016/j.jchf.2025.102590
Citations
2
Primary Topic
Heart Failure Treatment and Management
Type
article
Field-Weighted Citation Impact
2.78
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Temporal Changes in Biomarkers, Functional Status, and Quality of Life Prior to Adverse Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction

Bertram Pitt, Brian Lee Claggett, Mario Berger, Pardeep S. Jhund et al.
2 citations
JACC Heart Failure
Heart Failure Treatment and Management
2.78
article

Temporal Changes in Biomarkers, Functional Status, and Quality of Life Prior to Adverse Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction

Bertram Pitt, Brian Lee Claggett, Mario Berger, Pardeep S. Jhund, John J.V. McMurray, Laura Goea, Scott David Solomon, Muthiah Vaduganathan, Adriaan A. Voors, Andrea Scalise, Henri Lu, Michele Senni, Sanjiv J. Shah, Carolyn Lam, Katharina Mueller, Akshay S. Desai, Markus F. Scheerer, Faiez Zannad
article en
2 citations

Abstract

In a large HFmrEF/HFpEF trial population, clinically meaningful changes in readily available biomarkers, functional status, and patient-reported health status were observed in the months leading up to a clinical event. Monitoring these parameters may help identify patients at high risk for near-term adverse clinical events. (Finerenone Trial to Investigate the Efficacy and Safety Superior to Placebo in Patients With Heart Failure [FINEARTS-HF]; NCT04435626).

JACC Heart FailureVol. 13(10)
Northwestern University (US), Brigham and Women's Hospital (US), University Medical Center Groningen (NL), Harvard University (US), Inserm (FR), National University of Singapore (SG), University of Michigan (US), British Heart Foundation (GB), Ospedale Papa Giovanni XXIII (IT), National University Heart Centre Singapore (SG), National Heart Centre Singapore (SG), Bayer (Germany) (DE), University of Glasgow (GB), Université de Lorraine (FR), University of Lausanne (CH)
Openalex Percentile: Top 8%
Heart Failure Treatment and Management
2.78
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.